Orion Biotech Profile
Key Indicators
- Authorised Capital ₹ 0.50 M
as on 27-06-2024
- Paid Up Capital ₹ 0.14 M
as on 27-06-2024
- Company Age 20 Year, 8 Months
- Last Filing with ROC 31 Mar 2023
- Revenue -4.68%
(FY 2023)
- Profit -15.10%
(FY 2023)
- Ebitda -5.62%
(FY 2023)
- Net Worth 40.32%
(FY 2023)
- Total Assets 13.33%
(FY 2023)
About Orion Biotech
The Company is engaged in the Pharma Industry.
The Company's status is Active, and it has filed its Annual Returns and Financial Statements up until 31 March 2023. It's a company limited by shares with an authorized capital of Rs 0.50 M and a paid-up capital of Rs 0.14 M, as per Ministry of Corporate Affairs (MCA) records.
Abhishek Tulsyan and Sanjay Tulsyan serve as directors at the Company.
- CIN/LLPIN
U24231GJ2004PTC043922
- Company No.
043922
- Company Classification
Private Limited Indian Non-Government Company
- Incorporation Date
06 Apr 2004
- Date of AGM
30 Sep 2023
- Date of Balance Sheet
31 Mar 2023
- Listing Status
Unlisted
- ROC Code
Roc Ahmedabad
Industry
Company Details
- Location
Ahmedabad, Gujarat, India
- Telephone
- Email Address
- Website
- Social Media-
What products or services does Orion Biotech Private Limited offer?
Orion Biotech Private Limited offers a wide range of products and services, including Antibiotic Tablets & Capsules, Azithromycin Tablets, Pharma Franchise, PCD Pharma Franchise, Anti Infective Drugs & Medicines, Antibiotic Tablets, Capsule & Syrup.
Who are the key members and board of directors at Orion Biotech?
Board Members(2)
| Name | Designation | Appointment Date | Status |
|---|---|---|---|
Abhishek Tulsyan  | Whole-Time Director | 10-Oct-2014 | Current |
| Sanjay Tulsyan | Director | 01-Jan-2022 | Current |
Financial Performance of Orion Biotech.
Orion Biotech Private Limited, for the financial year ended 2023, experienced Minor drop in revenue, with a 4.68% decrease. The company also saw a substantial fall in profitability, with a 15.1% decrease in profit. The company's net worth Soared by an impressive increase of 40.32%.
- Key Matrics
- Balance Sheet
- Profit and Loss
- Cash Flow
- Ratios
| Metric |
| (FY 2022) | (FY 2021) | (FY 2020) | (FY 2019) | ||
|---|---|---|---|---|---|---|---|
| Total Revenue |
| ||||||
| Revenue from Operations |
| ||||||
| Total Assets |
| ||||||
| Profit or Loss |
| ||||||
| Net Worth |
| ||||||
| EBITDA |
|
What is the Ownership and Shareholding Structure of Orion Biotech?
In 2023, Orion Biotech had a promoter holding of 100.00%. Access key insights, ownership, including shareholding patterns, funding, foreign investors, KMP remuneration, group structure, and overseas investments.
Related Corporates (Common Directorship)
Zenon Lifesciences Private LimitedActive 9 years 8 monthsAbhishek Tulsyan and Sanjay Tulsyan are mutual person
Astrica Biomedics Private LimitedActive 11 years 5 monthsAbhishek Tulsyan and Sanjay Tulsyan are mutual person
- Tisenta Medicare India LlpActive 5 years 7 months
Abhishek Tulsyan and Sanjay Tulsyan are mutual person
Charges (Loans)
There are no open charges registered against the company as per our records.
How Many Employees Work at Orion Biotech?
Unlock and access historical data on people associated with Orion Biotech, such as employment history, contributions to the Employees' Provident Fund Organization (EPFO), and related information.
Deals i
Gain comprehensive insights into the Deals and Valuation data of Orion Biotech, offering detailed information on various transactions, including security allotment data. Explore the intricate details of financial agreements, mergers, acquisitions, divestitures, and strategic partnerships that have shaped Orion Biotech's trajectory.
Rating
Access the credit rating data, providing valuable insights into the company's creditworthiness and financial stability. Explore assessments from leading credit rating agencies, evaluating factors such as debt obligations, liquidity, profitability, and overall financial health.
Alerts
Stay informed about regulatory alerts and litigation involving and associated companies. Receive timely updates on legal proceedings, regulatory changes, and compliance issues that may impact the company's operations, reputation, and financial performance. Monitor litigation involving subsidiaries, joint ventures, and other affiliated entities to assess potential risks and liabilities.
